When is Stress Ulcer Prophylaxis Contraindicated?
Stress ulcer prophylaxis (SUP) is contraindicated—or more precisely, strongly recommended against—in critically ill patients who lack risk factors for gastrointestinal bleeding. 1, 2
Primary Contraindication: Absence of Risk Factors
The most definitive "contraindication" to SUP is the absence of bleeding risk factors. The 2024 SCCM/ASHP guideline and 2016 Surviving Sepsis Campaign guidelines explicitly recommend against SUP in patients without risk factors for GI bleeding 1, 2. This is not a true contraindication in the pharmacologic sense, but rather a strong recommendation to withhold therapy when the risk-benefit ratio is unfavorable.
Key Risk Factors That Justify SUP:
- Coagulopathy (OR = 4.3 for bleeding risk) 3
- Mechanical ventilation > 48 hours (OR = 15.6 for bleeding risk) 3
- Shock/hemodynamic instability 2
- Chronic liver disease 2
Clinical Algorithm:
- Assess for major risk factors (coagulopathy, mechanical ventilation >48h, shock, chronic liver disease)
- If none present → Do not initiate SUP 1, 2
- If risk factors present → Consider SUP with PPI or H2RA 1, 2
- When risk factors resolve → Discontinue SUP immediately 2
Relative Contraindications and Harm Considerations
While not absolute contraindications, certain situations warrant extreme caution or avoidance:
1. Patients with Chronic Liver Disease Receiving PPIs
Special populations such as cirrhotic patients may experience increased mortality when treated with PPIs 4. This creates a paradox since liver disease is also a risk factor for bleeding—requiring careful individualized assessment of bleeding risk versus harm from acid suppression.
2. Risk of Infectious Complications
SUP is associated with:
- Increased nosocomial pneumonia risk (OR = 1.35 with H2RAs vs sucralfate) 3
- Clostridium difficile-associated diarrhea 4
- Central line-associated bloodstream infections (30.6% vs 12.5% in one pediatric study) 5
These infectious risks may outweigh bleeding prevention benefits in patients without clear risk factors 4, 6.
3. Drug Interactions and Toxicity
- Clopidogrel interactions with PPIs (reduced antiplatelet efficacy) 4
- Hepatotoxicity and bone marrow toxicity with PPIs 4
- Neurologic manifestations with H2RAs 7
Critical Implementation Points
When to Withhold SUP:
- No mechanical ventilation AND no coagulopathy → NNT = 1,000 to prevent one bleeding event 3
- Enterally fed patients at low risk → Enteral nutrition itself probably reduces bleeding risk 2
- Patients with preadmission acid suppression without active indication → Discontinue if no new ICU-specific risk factors 2, 8
Common Pitfall to Avoid:
Inappropriate continuation beyond ICU is rampant—63% of patients without indication continue SUP on the ward, and 39% are discharged home on unnecessary prophylaxis 8. Discontinue SUP before ICU transfer when risk factors have resolved 2.
Evidence Quality Considerations
The evidence supporting routine SUP is surprisingly weak. The actual incidence of clinically important GI bleeding in modern ICUs is only 1.5-2.6% 3, 9, 3, and no mortality benefit has been demonstrated with routine SUP 4, 6. The Danish Society guidelines (2014) recommend against routine SUP outside clinical trials (GRADE 1C) 6.
The strongest evidence shows that only patients with both respiratory failure AND coagulopathy have meaningful bleeding risk (3.7%), requiring treatment of 27 patients to prevent one bleeding event 3. Without these factors, the NNT balloons to 1,000 3.
Bottom line: SUP should be withheld in the absence of documented risk factors, discontinued promptly when risk resolves, and never continued beyond the ICU without a specific ongoing indication 1, 2, 8.